VP, Global Medical Lead Rare Cardiology (Secondment - 12 Months)

WHY PATIENTS NEED YOU

The Vice President, Global Medical Lead Rare Cardiology is accountable for defining and executing the global medical strategy for Pfizer’s rare cardiology portfolio, with primary responsibility for ATTR cardiomyopathy (ATTR‑CM) and future rare cardiovascular assets.

This role provides enterprise‑level medical leadership across the full lifecycle ensuring that medical strategy is scientifically robust, patient‑centric, and aligned with Pfizer’s long‑term disease leadership ambitions. This ability to anticipate change, navigate increasing competition, and continuously adapt medical strategy, while maintaining scientific rigor, patient‑centricity, and long‑term disease leadership is required.

WHAT YOU WILL ACHIEVE

The Team Lead will serve as a senior medical partner to Regulatory, HEOR, Commercial, and Market Access, Safety while leading high‑impact external engagement with regulators, scientific leaders, and healthcare systems globally.

• Will be the strategic external scientific face and internal point person of our cardiology department, advocating Pfizer as leader partner, supporting the evidence generation and scientific excellence by overseeing global evidence‑generation strategy, including, clinical and post‑approval evidence, real‑world evidence and patient‑centric data and Investigator‑initiated research and medical grants.

• Will ensure high‑quality scientific communications, including publications, congress strategy, and advisory boards. Translate evidence into actionable insights for clinicians, regulators, and payers.

• Will lead and develop high‑performing global medical teams, foster a culture of scientific rigor, accountability, inclusion, and talent development.

• Will influence effectively complex, matrixed global organizations and serve as a role model for Pfizer Leadership Capabilities.

The Global Medical Lead will need to show high level of scientific expertise in cardiology and rare disease and will benefit from an established and strong network of international KOLs in order to function as a peer and leader for medical affairs in developing this ambition.

A key element of the work will be to continuously develop the medical strategy for the rare cardiology life cycle in a very rapid changing landscape and in close collaboration International and US stakeholders and various cross functional partners. Collaboration across functions, solution-orientation and leadership skills are key criteria for a successful candidate while showing strong ability to prioritize and focus strategies based on specific area requirements.

HOW YOU WILL ACHIEVE IT

Global Medical Strategy & Disease Leadership

Define and lead the global medical strategy for rare cardiology on ATTR‑CM. Drive a disease‑centric approach, integrating biology, diagnostics, treatment pathways, and long‑term outcomes. Ensuring medical strategy supports sustained disease leadership, not only near‑term success. Deliver impact amid shifting standards of care, emerging competitors, and evolving healthcare system expectations while maintaining scientific rigor, patient‑centricity, and long‑term disease leadership.

• Able to develop the appropriate medical strategy regarding a dynamic and increasingly competitive environment. Anticipate scientific, clinical, and competitive shifts, translating them into proactive medical strategies. Ensure medical positioning evolves in line with emerging data, new entrants, and changing treatment paradigms.

• Own and define the global evidence‑generation vision for Rare Cardiology, ensuring data strategies anticipate future clinical, regulatory, and competitive needs, not only current requirements.

• Ensure evidence generation directly supports disease leadership, differentiation, and sustained relevance in an increasingly competitive environment.

• Translate evolving science, clinical practice, and competitive intelligence into proactive evidence priorities, adapting data plans as standards of care and treatment paradigms evolve.

• Ensure high‑quality scientific communications, including publications, congress strategy, and advisory boards.